Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity

Vaccine

Volumn 30, Issue 12, 2012, Pages 2212-2219

  Ott, J J ^a   Stevens, G A ^a   Groeger, J ^b   Wiersma, S T ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Age distribution; Epidemiology; Hepatitis B; Hepatitis B surface antigen (HBsAg); Modeling; Prevalence; Seroepidemiologic studies; Systematic review

Indexed keywords

HEPATITIS B SURFACE ANTIGEN;

AFRICA; AGE DISTRIBUTION; ARTICLE; AUSTRALIA; CENTRAL AMERICA; DISEASE SURVEILLANCE; ENDEMIC DISEASE; EUROPE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HUMAN; MIDDLE EAST; PRIORITY JOURNAL; RISK ASSESSMENT; SEROPREVALENCE; SEX DIFFERENCE; SOUTH AND CENTRAL AMERICA; SOUTHEAST ASIA; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GEOGRAPHY; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; SEX FACTORS; WORLD HEALTH; YOUNG ADULT;

EID: 84857358267     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.116     Document Type: Article

References (35)

1. Hyams K.C. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995, 20:992-1000.
2. McMahon B.J., Alward W.L., Hall D.B., et al. Acute hepatitis B virus infection: relation of age to clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985, 151:599-603.
3. Weinbaum C.M., Williams I., Mast E.E., Wang S.A., Finelli L., Wasley A., et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008, 57:1-20.
4. Wong S.N., Lok A.S. Treatment of hepatitis B: who, when and how. Arch Intern Med 2006, 166:9-12.
5. Goldstein S.T., Alter M.J., Williams I.T., et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002, 185:713-719.
6. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34:1329-1339.
7. Ott J.J., Ullrich A., Mascarenhas M., Stevens G.A. Global cancer incidence and mortality caused by behavior and infection. J Public Health (Oxf) 2011, 33:223-233. Epub 2010 Oct 8.
8. Shepard C.W., Simard E.P., Finelli L., Fiore A.E., Bell B.P. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006, 28:112-125.
9. Bréchot C., Thiers V., Kremsdorf D., Nalpas B., Pol S., Paterlini-Brechot P. Persistent hepatitis B virus: clinically significant of purely occult. Hepatology 2001, 34:194-203.
10. McQuillan G.M., Coleman P.J., Kruszon-Moran D., Moyer L.A., Lambert S.B., Margolis H.S. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999, 89:14-18.
11. Wasley A., Kruszon-Moran D., Kuhnert W., Simard E.P., Finelli L., McQuillan G., et al. The prevalence of Hepatitis B Virus infection in the United States in the Era of Vaccination. J Infect Dis 2010, 202:192-201.
12. DISMOD III: DISMOD III complete repository of the DisMod code: Available from: https://github.com/aflaxman/gbd/tree/master/dismod3.
13. GBD 2005 Study. Global Burden of Diseases, Injuries and Risk Factors Study operations manual (final draft, January 2009). Available from: http://www.globalburden.org/.
14. Hoofnagle J.H. Chronic hepatitis B. N Engl J Med 1990, 323:337-339.
15. Viviani S., Jack A., Hall A.J., et al. Hepatitis B vaccination in infancy in the Gambia: protection against carriage at 9 years of age. Vaccine 1999, 17:2946-2950.
16. Whittle H., Jaffar S., Wansbrough M., et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002, 325:569-573.
17. Coursager P., Leboulleux D., Soumare M., et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 1994, 21:250-254.
18. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010, International Agency for Research on Cancer, Lyon, France, [Internet] Available from: http://globocan.iarc.fr.
19. WHO vaccine-preventable diseases: monitoring system. 2010 global summary. WHO; 2010. Available from: http://www.who.int/immunization/documents/who_ivb_2010/en/index.html.
20. Report of the Safe injection Global Network (SIGN) meeting 2010. WHO; 2010. Available from: http://www.who.int/injection_safety/toolbox/sign2010_meeting.pdf.
21. World Health Organization (WHO) Hepatitis B position statement. Wkly Epidemiol Rec 2009, 84:405-420.
22. Centers for Disease Control and Prevention (CDC) Surveillance for acute viral hepatitis - United States, 2006. MMWR Morb Mortal Wkly Rep 2008, 57:SS2.
23. Rantala M., van de Laar M.J.W. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill 2008, 13.
24. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
25. Lin Y.C., Chang M.H., Ni Y.H., Hsu H.Y., Chen D.S. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003, 187:134-138.
26. Lee C.L., Hsieh K.S., Ko Y.C. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev 2003, 12:57-59.
27. Liao S.S., Li R.C., Li H., et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999, 17:2661-2666.
28. World Health Organization Progress towards meeting the 2012 hepatitis B control milestone: WHO Western Pacific Region, 2011. Wkly Epidemiol Rec 2011, 86(19):180-188.
29. Pan C.Q., Zhang J.X. Natural history and clinical consequences of hepatitis B virus infection. Int J Med Sci 2005, 2:36-40.
30. Livingston S.E., Simonetti J.P., McMahon B.J., et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007, 195:5-11.
31. Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005, 12:111-124.
32. Centers for Disease Control and Prevention (CDC) Screening for chronic hepatitis B among Asian/Pacific Island populations - New York City, 2005. MMWR Morb Mortal Wkly Rep 2006, 55:505-509.
33. Maffre C., Le Strat Y., Delarocque-Astagneau E., et al. Prevalence of hepatitis B and C virus infection in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010, 82:546-555.
34. McMahon B.J., Schoenberg S., Bulkow L., et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives. Am J Epidemiol 1993, 138:544-549.
35. Ott J.J., Paltiel A.M., Winkler V., Becher H. Chronic disease mortality associated with infectious agents: a comparative cohort study of migrants from the Former Soviet Union in Israel and Germany. BMC Public Health 2008, 8:110.